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Spontaneous reportAbstract Objectives: The aim of this study was to determine the frequency and proﬁle of sponta-
neous reports of Adverse Drug Reactions (ADRs) and quality deviations in a Brazilian teaching
hospital and propose a consistent classiﬁcation to study quality deviations.
Methods: This is a descriptive and retrospective study involving the analysis of spontaneous
reports of ADRs and quality deviations in 2010. ADRs were classiﬁed according to the reaction
mechanism, severity, and causality. The drugs were classiﬁed according to their therapeutic classes
and symptoms according to the affected organ. The quality deviations were classiﬁed according to
the type of deviation and type of medicine available in the Brazilian market.
Results: A total of 68 forms were examined; ADRs accounted for 39.7% of the notiﬁcations,
while quality deviations accounted for 60.3%. ADRs occurred more frequently in men (51.9%)
and adults (63.0%). The skin (28.0%) was the most affected organ, while anti-infectives (40.7%)
Adverse drug reactions and quality deviations 131were the therapeutic class that caused the most ADRs. The most common ADRs were type B
(74.0%), moderates (37.0%), and probables (55.6%). In relation to quality deviations, the most fre-
quent notiﬁcations were breaks, splits and leaks (20.9%) and related to generic drugs (43.9%).
Conclusion: The classiﬁcation system to study quality deviations was clear and consistent. This
study demonstrated that practices and public policies related to more effective pharmacovigilance
need to be implemented so that the number of spontaneous reports increases.
ª 2014 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Pharmacovigilance is deﬁned as the science and activities
related to detection, evaluation, understanding and prevention
of adverse effects or any other drug related problem (WHO,
2002). Postmarketing surveillance on the effects of drugs in
clinical practice is essential and spontaneous reporting of
Adverse Drug Reactions (ADRs) is important because it
increases drug safety knowledge (Wyswski and Swartz,
2005). The World Health Organization (WHO) deﬁnes ADR
as any response to medication that is harmful and unintended
that occurs at doses normally used in humans for prophylactic,
diagnostic or therapeutic purposes (WHO, 2002). Therapeutic
failures such as drug abuse, accidental or intentional poisoning
and adverse events that occur as a result of non-adherence to
pharmacotherapy or medication errors are not considered an
ADR (Lazarou et al., 1998).
The detection and evaluation of ADRs in hospitals are
required because of the possibility of identiﬁcation of severe
reactions, reactions of new drugs, increased frequency of
known reactions, unknown effects, identiﬁcation of the risk
factors and possible dissemination of information among clini-
cians and health professionals (Cereza et al., 2010). Many
studies have been conducted to characterize the ADR proﬁle
found in hospitals, evaluating medicaments, therapeutic classes
and demographic data of affected patients, medications con-
comitantly used for a certain person, type of ADR, affected
organs, severity and causality relation (Jose and Rao, 2006;
Sriram et al., 2011; Lobo et al., 2013).
In several countries, pharmacovigilance is based on the
spontaneous reporting aimed at ADR detection after commer-
cialization (Cereza et al., 2010). However, a major limitation of
this model is that only a small part of all ADRs are reported
(Hazell and Shakir, 2006). A previous reports showed that sev-
eral factors were associated with under-reporting such as igno-
rance (only severe ADRs need to be reported), difﬁdence (fear
of appearing ridiculous for reporting merely a suspected
ADR), lethargy (e.g., lack of interest or time), indifference
(one case from an individual practitioner does not contribute
to medical knowledge), insecurity (causality between a drug
and an adverse event is hard to determine) and complacency
(only safe drugs are allowed on the market) (Lopez-Gonzalez
et al., 2009).
Another issue of pharmacovigilance is quality deviation.
This notiﬁcation occurs when the required quality parameters
are not followed for commercialization or the registration pro-
cess of a pharmaceutical product and can result in health prob-
lems. Quality deviations are simple to evaluate, because as the
absence of a label, the presence of foreign bodies or color
changes of a drug are issues that are obvious to observe(Capucho, 2008). Few studies have reported on quality devia-
tions and strict classiﬁcations for quality deviations do not
exist; however, monitoring the quality of products used in
patient care is extremely important because it may pose a risk
to patient safety. This study is the ﬁrst to propose a consistent
quality deviation classiﬁcation.
The aim of this study was to determine the frequency and
proﬁle of spontaneous reports for ADRs and quality devia-
tions, report the types of drugs involved and characterize the
most common clinical manifestations associated with ADRs
and its severity in a Brazilian teaching hospital so as to alert
health professionals, regulatory authorities and patients who
use medicaments on the importance of reporting ADRs and
quality deviations.2. Methods
This was a descriptive and retrospective study which was con-
ducted in a teaching hospital (403 beds) in Sa˜o Paulo, Brazil.
The study occurred from January 2010 to December 2010
and it involved the analysis of ADRs and quality deviations
of spontaneous reports. This study was evaluated and
approved by the Ethics Committee of the Institution.
Health professionals from different specialties could report
alleged ADRs and quality deviations with an application form
which was sent to the pharmacovigilance section of the hospi-
tal. The pharmacist analyzed the ADR and quality deviation
notiﬁcations to supplement the data. In the case of an ADR,
the notiﬁcation was reviewed, interviews with the professionals
involved in the case were made and the patients were observed,
to obtain more details and update monitoring, until the case
was resolved or the patient was discharged.
2.1. Adverse Drug Reactions (ADRs)
Each application form for the patients (in- and outpatients)
was analyzed, such that ADRs that occurred during hospital-
ization and ADRs that led to hospitalization were examined.
Patients of both genders and all ages were included in this
study while excluded notiﬁcations that involved patients that
were accidentally or intentionally poisoned, had ADRs that
were associated with blood products from transfusions, drug
overdose and intoxication.
The notiﬁcations included in this study were analyzed
according to the patient’s gender, age, comorbidities, possible
risk factors, allergies, ADR description and start date as well
as the involved and suspected medicaments (generic name,
administration, dose and posology). Ages were separated into
three groups: pediatric (0–18 years old), adults (19–59 years
132 M.B. Visacri et al.old), as well as geriatric populations (over 60 years old) (Lobo
et al., 2013).
The Anatomical Therapeutic Chemical Classiﬁcation
(ATC) (WHO, 2013b) was used to classify medicaments in
therapeutic classes while the World Health Organization-
Adverse Reaction Terminology (WHO-ART) (WHO, 1997)
was used to classify the organs affected by the ADR. Each
reaction was characterized according to the reaction mecha-
nism, which used the type A and type B classiﬁcation system
proposed by Rawling and Thompson, 1998; causality, which
used the doubtful, possible, probable, and deﬁnite classiﬁca-
tion system according to Naranjo Algorithm (Naranjo et al.,
1981); and severity, which used mild, moderate, severe, and
lethal classiﬁcations according to Coeˆlho et al. (1999). The
management strategies for the ADRs were categorized as drug
withdrawal, dose reduction, additional treatment or a stable
regimen without additional treatment (Lobo et al., 2013).
2.2. Quality Deviations
Since the International Nonproprietary Names (INN) (WHO,
2013a) aid in identifying the active pharmaceutical ingredients,
the notiﬁcations of the quality deviations were examined by
collecting the medicament’s trade name that was causing the
deviations, its dosage forms, the supplier’s name, the notifyingTable 1 Type of quality deviations.
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aggregunit and the description of complaints. This information was
classiﬁed according to the types of medicaments available in
the Brazilian market and the type of deviation (Table 1).
The types of medicaments were classiﬁed as brand-name
drugs, generic drugs, similar drugs and compounded drugs.
A brand-name drug is a prescription medication that has been
approved by the Food and Drug Administration (FDA) based
on comprehensive toxicological data and human clinical trials
that demonstrate that the drug is safe and effective and chem-
ical evaluations prove that the product can be made consis-
tently to a high quality standard (Gudeman et al., 2013).
After the patent protection period of the brand-name drug
expires, generic drugs may be approved by the FDA. Generic
drugs have been tested and conﬁrmed to be bioequivalent to
the brand-name product (Gudeman et al., 2013); thus, generic
drugs are copies of brand-name drugs and are the same as
those brand-name drugs in dosage form, safety, strength, route
of administration, quality, performance characteristics, and
intended use (FDA, 2013). A similar drug is one that has the
same active ingredients, concentration, dosage form, route of
administration, dosage and therapeutic indication, which is
equivalent to the drug registered in the federal agency respon-
sible for monitoring health. It can differ in characteristics
related to size and shape of the product, shelf life, packaging,
and labeling, excipients and vehicle must always be identiﬁediption
tions related to the shape of the product and package. Since it is an
al part of the product, it also includes the technical problems found
product handling, diﬃculty in opening (which may cause injury to
anipulator) and type of primary package incompatible with the
cteristic of the medicament (as colorless glass ampoules for
aments subject to photolysis)
s, splits, holes and microholes in vials, ampoules, and sealed ﬂask
ules. It can cause leaks bringing on environmental and individual
mination with the substance
of identiﬁcation, such as label and/or fundamental information that
ine the best use of the product, such as concentration, dosage, name
dministration of the medicine
ation presented on the package, labels and instructions that generate
kind of confusion or diﬃculty in reading. This includes package or
ercial names similar to another product, diﬃculty in reading
ation due to poor print quality or small letters and the presence of
than one lot number and/or validity
of the product in a sealed primary package and/or the absence of
ry package in a sealed secondary package and/or volume below that
ed in the label
resence of a foreign body in the product (undissolved particulate
ial contaminants such as dust, fabric ﬁbers, glass fragments, leachate
ial in covers/plastic and any other material that may pass into the
ct during manufacturing or develop during storage) and dirtiness in
imary package
changes, odor, taste, limpidity (related to turbidity, and does not
e particulate material), viscosity and original consistency of the
ct
ty deviations that compromise the physical and chemical
cteristics such as hardness, friability, thickness and coating of tablets,
les oscillation and ﬁssures and diﬃculties in rebuilding powder into
on/injectable suspension
llization, precipitation, incomplete redistribution of the dispersed
in the dispersion environment (sedimentation, ﬂocculation and
ation of suspended particles) and emulsion coalescence
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necessary when an FDA-approved drug is not available or
appropriate for the patient, or must be altered in some man-
ner, such as strength or route of delivery (Gudeman et al.,
2013). It is produced by pharmacy compounding, deﬁned by
the FDA as the combining, mixing, or altering of the ingredi-
ents to create a customized medication for an individual
patient in response to a licensed practitioner’s prescription
(Galson, 2003).
To evaluate the amount of quality deviations distributed
according to the type of the medicament, an assessment was
made to estimate the number of generic, similar, brand-name
and compounded drugs purchased by the hospital. Since med-
icaments are purchased by price analysis, the suppliers and dis-
tributors may vary from one purchase to another; thus
assessing the hospital’s stockroom is only one way to evaluate
the amount of quality deviations distributed according to the
type of the medicament.3. Results
The pharmacovigilance section of the hospital received 68 noti-
ﬁcations in 2010, 27 were ADRs (39.7%) and 41 were quality
deviations (60.3%).
Three of 27 ADRs could have been avoided; one with a
dose adjustment according to renal clearance; one by changing
the posology and velocity of the infusion and one by previ-
ously checking for drug interactions. The most frequent routes
of administration were intravenous (17; 63.0%), oral (9;
33.3%) and intramuscular (1; 3.7%).
Three cases of ADRs led to hospitalization (11.1%) while
12 (44.4%) patients were already in the hospital and the
remaining 12 (44.4%) were outpatients that did not require
hospitalization. The ADRs occurred more frequently in males
(14; 51.9%) than in females (13; 48.1%). and more often in
adults (17; 63.0%) as compared to the geriatric (8; 29.6%)
and pediatric patients (2; 7.4%).
The therapeutic classes and affected organs are presented in
Tables 2 and 3, respectively. Anti-infective drugs (systemic)
were involved in 11 notiﬁcations (40.7%), followed by antineo-
plastic and immunomodulating agents (10; 37.0%). Inﬂiximab
was the medicament that caused the most ADRs. The most
frequent symptom associated with ADRs was skin reactions
which were present in 16 forms (28.0%) and, in most cases,
involved a rash and urticaria.
Table 4 shows the results regarding the reaction mecha-
nism, severity, causality and management of ADRs. Analysis
of the reaction mechanism of the ADRs identiﬁed 20 type B
(74.0%) for example severe cases of anaphylaxis and the Ste-
vens–Johnson syndrome, while 7 type A (26.0%) as the case
of coagulation disorders, ecchymosis and petechiae after war-
farin administration. In regard to severity, 10 reactions
(37.0%) were classiﬁed as moderate and these cases included
hallucinations to haloperidol and pancreatitis to atazanavir.
Nine reactions were classiﬁed as mild (33.3%) and one
(3.7%) reaction was lethal, which resulted in the patient’s
death after agranulocytosis by clozapine. According to the
relation analysis of causality, which uses the Naranjo Algo-
rithm, 15 reactions (55.6%) were considered probable and only
one reaction (3.7%) was deﬁned because of edema where pac-
litaxel was infused. For management analysis, a patient couldhave one or more treatments. Drugs were added to relieve the
symptoms for 55.6% of the patients while treatment with the
offending drug was interrupted in 51.3% of the patients and
another drug was substituted with the offending drug in
29.6% of cases. Treatment remained the same in 11.1% of
the patients and management information for one patient
(3.7%) was unavailable.
Twelve quality deviations (29.2%) were not identiﬁed to the
notifying unit, 8 were from the central pharmacy (19.5%) and
7 were from the chemotherapy pharmacy (17.1%). The dosage
forms involved in quality deviations were an injectable solu-
tion (17; 41.4%), powder for solution/injectable suspension
and oral solution (7; 17.1% and 7; 17.1%, respectively), tablet
(6; 14.7%), enema (2; 4.9%), syrup and oral suspension (1;
2.4% and 1; 2.4%, respectively).
Table 5 shows the notiﬁcation frequency of the types of
quality deviations. Breaks, splits and leaks were the deviations
that appeared the most as well as the lack of product and lower
volume; thus, each of these deviations had the same number of
notiﬁcations (9; 20.9%). There were 8 notiﬁcations of broken
products (18.6%) and of these 8, 2 were related to biological
risk (ifosfamide and 5-ﬂuorouracil) and 4 were of high ﬁnan-
cial value (ifosfamide, 5-ﬂuorouracil, human serum albumin
and zoledronic acid).
The lack of identiﬁcation – information are deviations that
require attention because the can induce errors in medication
administration to the patient. Five (11.7%) quality deviations
were related to this production defect, and 4 (9.3%) corre-
sponded to unidentiﬁed products (i.e., missing labels) and 1
(2.3%) notiﬁcation was about 180 bottles of neomycin (an
antibiotic compounded drug) that lacked information regard-
ing the dispensing of medication. Deviations related to the
poor quality of information (7.0%) may also harm the patient
as was the case of 2 similar ampoules, amiodarone (antiar-
rhythmic) and acetylcysteine (mucolytic agent) which had the
information written very clearly in yellow with the product
name and concentration. The anatomical packing problems
appeared in 5 notiﬁcations (11.7%).
A few product cases contained foreign bodies and dirtiness
(4; 7.0%) and this potential problem may indicate biological
contamination. The complaints related to this deviation corre-
sponded to medicaments that contained foreign bodies such
that 5 bottles of L-carnitine syrup (a compounded drug) con-
tained a dark ﬁber which after microbial analysis was con-
ﬁrmed as Penicillium sp. Additional complaints were related
to an enema glycerin solution that contained dark ﬁber inside
the bottle. After analysis, a microhole was found in the pri-
mary packaging that allowed air entry and consequently
microbial contamination.
The notiﬁcation frequency of quality deviations regarding
the type of drugs available in the Brazilian market were 18
notiﬁcations (43.9%) involved in generic drugs, 11 (26.8%)
involved in similar drugs, 7 (17.1%) involved in compounded
drugs and 5 (12.2%) involved in brand-name drugs. After sam-
pling the 187 medicaments in the hospital stockroom, it was
estimated that 48.7% are similar drugs, 36.4% are generic
drugs, 11.7% are brand-name drugs and 3.2% are com-
pounded drugs.
Regarding the number of product units showing deviation,
besides the 180 bottles of neomycin that lacked information
regarding the dispensing of the medication, the 2 notiﬁcations
(4.6%) of physicochemical changes in solids corresponded to a
134 M.B. Visacri et al.total of 4500 tamoxifen tablets (similar drug) which had a
change in its hardness property such that the tablets became
fragmented when it was removed from the blister. Thus, in
absolute numbers, 198 compounded, 26 generic, and 4
brand-name drugs presented quality deviations, but quantiﬁca-
tions were made by notiﬁcation; thus, from the 4515 units of
similar products that presented quality deviations, 4500 units
corresponded to only 2 quality deviation notiﬁcations.
4. Discussion
A major limitation of the spontaneous ADR reporting system
is that ADRs are under reported (Gonzalez-Gonzalez et al.,
2013). In 2010, the pharmacovigilance sector received 27 noti-
ﬁcations of ADRs which is not much if the number of hospital
beds and its complexity level are taken into consideration;
thus, the under-reporting phenomenon caused by this sponta-
neous reporting method, prevents the health system from
expanding knowledge regarding the safety and quality of med-
icaments, which makes it difﬁcult to improve and prevent
ADRs. One-hundred and sixteen reporting forms that involved
269 medications and 204 reactions were recorded from a study
that was conducted in a hospital in Fortaleza (Brazil). That
study occurred from January to December 2007 in a teaching
hospital, with 425 beds. Only 1 form (0.9%) was spontane-
ously reported, and the other forms were obtained by active
surveillance (115; 99.1%); thus, this study reinforced that
higher professionals need to be involved in spontaneous
reporting and showed the importance of the active surveillance
(Romeu et al., 2011).Table 2 Therapeutic classes and drugs associated with Adverse Dr
Therapeutic Classes (ATC) Code (A
Anti-infectives for systemic use (J)
J01XA0
J02AA0
J01CA0
J01GB0
J01MA
J01XX0
J04AC0
J04AK0
J05AE0
Antineoplastic and immunomodulating agents (L)
L04AB0
L01XA
L01CB0
L01CD
L01CD
L01DC
L01XA
Nervous system (N)
N03AF
N05AD
N05AH
N06DA
Alimentary tract and metabolism (A)
A11CC
Blood and blood forming organs (B)
B01AAIn the present study, the ADRs occurred more frequently in
men and in the adult patients. These data are consistent with
the previous Indian study that showed the same characteristics
in gender (61% for men) but differed in age since ADRs
occurred more frequently in patients over the age of 60 years
(56%) (Sriram et al., 2011). In the hospital in Fortaleza, Brazil,
ADRs were mostly prevalent in men (81.9%) and in 15–
29 year olds (42.4%); the medicament that was most frequently
associated with ADR was dipyrone (32.8%), and the skin was
the most affected organ (59.3%) (Romeu et al., 2011). In the
present study, dermatological reactions also comprised the
ADR proﬁle, which was often observed as a rash, urticaria,
and a severe case of the Stevens–Johnson syndrome.
The group of medicaments most often involved with ADR,
in this study, was the anti-infectives (systemic) which are the
most prescribed medicament in hospitals. A prior study dem-
onstrated an association between antibiotic use and risk of
adverse reactions, which caused dermatological, hepatical, car-
diovascular and central nervous system reactions (Aagaard
and Hansen, 2009). In addition to adverse reactions, irrational
use of antibiotics leads to the resistance of microorganisms and
an increase incidence of multi-resistant bacterial infections in
hospitals (Sharma et al., 2005).
Inﬂiximab, an immunomodulating agent, was the main
medicament that was involved with ADR and was associated
with reactions of urticaria, dyspnea, redness and facial swelling
at the time of infusion. Inﬂiximab consists of an anti-TNF
monoclonal antibody that is used to treat Crohn’s disease
and rheumatoid arthritis. Since it is composed of a murine pro-
tein, adverse effects related to hypersensitivity occur frequentlyug Reactions (ADRs).
TC) Drug Total number (%)
11 (40.7)
1 Vancomycin 2 (7.4)
1 Amphotericin 2 (7.4)
4 Amoxicillin 1 (3.7)
3 Gentamicin 1 (3.7)
02 Ciproﬂoxacin 1 (3.7)
8 Linezolid 1 (3.7)
1 Isoniazid 1 (3.7)
1 Pyrazinamide 1 (3.7)
8 Atazanavir 1 (3.7)
10 (37.0)
2 Inﬂiximab 3 (11.1)
01 Cisplatin 2 (7.4)
1 Etoposide 1 (3.7)
01 Paclitaxel 1 (3.7)
02 Docetaxel 1 (3.7)
01 Bleomycin 1 (3.7)
02 Carboplatin 1 (3.7)
4 (14.9)
01 Carbamazepine 1 (3.7)
01 Haloperidol 1 (3.7)
02 Clozapine 1 (3.7)
03 Rivastigmine 1 (3.7)
1 (3.7)
04 Calcitriol 1 (3.7)
1 (3.7)
03 Warfarin 1 (3.7)
Table 3 Frequency of Adverse Drug Reactions (ADRs) in
affected organ.
Aﬀected organ Description Total number
(%) n= 57
Skin 16 (28.0)
Rash 5 (8.8)
Urticaria 4 (7.0)
Hyperpigmentation 2 (3.4)
Itch 2 (3.4)
Stevens–Johnson syndrome 1 (1.7)
Maculopapular rash 1 (1.7)
Alopecia 1 (1.7)
General 13 (22.8)
Malaise 3 (5.3)
Fever 2 (3.4)
Anaphylaxis 1 (1.7)
Infusion site swelling 1 (1.7)
Sweating 1 (1.7)
Fatigue 1 (1.7)
Prostration 1 (1.7)
Generalized edema 1 (1.7)
Intrathoracic pressure 1 (1.7)
Facial edema 1 (1.7)
Gastrointestinal 7 (12.3)
Nausea 4 (7.0)
Vomiting 1 (1.7)
Pancreatitis 1 (1.7)
Epigastric pain 1 (1.7)
Central and peripheral
nervous system
5 (8.8)
Dizziness 2 (3.4)
Trembling 2 (3.4)
Restlessness 1 (1.7)
Extra-cardiac vascular
system disturbance
3 (5.3)
Facial redness 3 (5.3)
Blood dyscrasias 3 (5.3)
Agranulocytosis 1 (1.7)
Thrombocytopenia 1 (1.7)
Leukocytosis 1 (1.7)
Psychiatric disorder 1 (1.7)
Hallucination 1 (1.7)
Other 9 (15.8)
Dyspnea 5 (8.8)
Acute renal failure 1 (1.7)
Hypotension 1 (1.7)
Ecchymosis 1 (1.7)
Petechiae 1 (1.7)
Table 4 Reaction mechanism, severity, causality and man-
agement of Adverse Drug Reactions (ADRs).
Frequency
n %
Reaction mechanism
Type A 7 26.0
Type B 20 74.0
Severity
Lethal 1 3.7
Severe 7 26.0
Moderate 10 37.0
Mild 9 33.3
Causality
Deﬁnite 1 3.7
Probable 15 55.6
Possible 11 40.7
Management
Added another drug to relieve the symptoms 15 55.6
Stopped the medication 14 51.9
Substituted another drug 8 29.6
No change 3 11.1
Reduced the dose 1 3.7
No informations 1 3.7
Adverse drug reactions and quality deviations 135during infusion, because of the formation of inﬂiximab anti-
bodies (Kolho et al., 2007). In this study, the adverse reactions
occurred on the eighth and tenth application, one of them in a
female patient, aged 14.
The proﬁle of ADRs in this study can be characterized as
type B, moderate severity and probable causality. This indi-
cates that the reactions are often unpredictable, not dose-
related, that changes the patient’s normal activity and causes
or prolongs hospitalization. Also, reactions whose signs and
symptoms are well described in the literature, are evident, eas-
ily diagnosed, but difﬁcult to prove since there are an immense
number of diseases and medications and the suspected medica-
ment was not re-administered to the patient. In a Brazilianstudy, most reactions were mild (72.0%) and probable
(47.5%) (Coeˆlho et al., 1999) while in the Indian study, 42%
of the reactions were possible, 30% were deﬁned and 23%
were probable (Jose and Rao, 2006).
The quality deviations revealed technical problems during
production, possible biological contamination, inadequate
storage and transportation of the product (temperature, lumi-
nosity and humidity). The medicaments with quality devia-
tions may cause adverse events in cases of contamination or
lead to ineffective therapy in patients if the active ingredient
is degraded. The quality deviations were reported more fre-
quently than ADRs in this study and the same results were also
observed by Bezerra et al. (2009), in a hospital in the Mid-West
Region of Brazil.
Breaks and leaks accidentally expose professionals and
patients to biological risks. Quality deviations in expensive
medicaments that are essential for a procedure or therapy
may impair the performance of vital activities that are required
for patient survival. Thus, for quality deviation classiﬁcations
in ‘‘severe’’ and ‘‘not severe’’, it should be developed as well as
the Naranjo algorithm for ADR, that took into account the
possibility of harm to patients and health professionals,
according to their ﬁnancial importance and its relevance to
the patient.
Quality deviations may be inconvenient to the hospital in
the medication process; however, the suppliers must replace
the defective medications or improve the product’s quality.
Thus, most of notiﬁed suppliers replaced the defective prod-
ucts and the industries issued quality control and quality assur-
ance reports that claimed the products were not qualiﬁed;
however, and in regard to the microhole in the primary pack-
aging of the enema glycerin, the company offered to change
the supplier of the bag.
Bismuth subsalicylate, a compounded product, had a valid-
ity of 180 days but after observing the instability in suspension,
Table 5 Frequency of notiﬁcations regarding the types of quality deviations.
Type of quality deviations Description of quality deviations Total number (%) (n= 43*)
Breaks/splits/leaks 9 (20.9)
Breaks 8 (18.6)
Split 1 (2.3)
Lack of product/lower volume 9 (20.9)
Lower volume than declared on the label 4 (9.3)
Secondary package without primary package 3 (7.0)
Primary package without the product 2 (4.7)
Lack of identiﬁcation – information 5 (11.6)
Ampoules and ﬂask without identiﬁcation/label 4 (9.3)
Lack of administration information 1 (2.3)
Package anatomical problems 5 (11.6)
Problem during handling 3 (7.0)
Ampoule very hard 1 (2.3)
Deviation of blister quality 1 (2.3)
Poor quality of information 3 (7.0)
Similar ampoules 2 (4.7)
Reading diﬃcult 1 (2.3)
Foreign body – dirtiness 4 (9.3)
Dark ﬁlament 4 (9.3)
Organoleptic changes 3 (7.0)
Color change 2 (4.7)
Turbidity 1 (2.3)
Physicochemical changes (liquid/semi-solid) 3 (7.0)
Crystallization 2 (4.7)
Formation of solid matter 1 (2.3)
Physicochemical changes (solid) 2 (4.7)
Hardness change 2 (4.7)
* Total of 43 quality deviations, because two medicaments presented more than one type of quality deviations.
136 M.B. Visacri et al.its validity was changed to 90 days to ensure medicament’s sta-
bility. In the case of the alteplase, a packing anatomical prob-
lem was evident during product handling and the hospital staff
learned how to properly handle it from a nurse in another
sector.
The hospital where this study was conducted acquires medi-
cament through a price analysis; thus, most medicaments are
similar and generic drugs. The acquisition of similar medica-
ments is higher than the generic drug but the number of gen-
eric notiﬁcations was higher than the similar notiﬁcations;
thus, this may suggest that a higher quality control and inspec-
tion should be performed, even if these generic drugs have ful-
ﬁlled the quality requirements. There is a lack of information
in the literature regarding quality deviations; thus, further dis-
cussion of quality deviations is impossible.5. Conclusions
The classiﬁcation system to study quality deviations was clear
and consistent. This study demonstrated that practices and
public policies related to more effective pharmacovigilance
need to be implemented so that the number of spontaneous
reports increases. In conclusion, it is necessary to increase
the number of spontaneous reports and improve the quality
of notiﬁcations, promote active surveillance in hospitals, and
conduct training of healthcare professionals. Further, educa-
tion related to pharmacovigilance activities and its importancein hospitals (which notify and how to notify) as well as
improving the production, quality control, transport, storage,
and distribution of pharmaceutical products, primarily in
generics and similar drugs, and will ensure safer drug use in
Brazilian hospitals.
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